Astrana Health, Inc. (formerly Apollo Medical Holdings, Inc.) — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; this is an annual report, not a standalone fourth-quarter filing. The company operates a physician-centric, risk-bearing healthcare platform, principally in California, with IPAs, management services, clinics, hospitalists, and a Medicare ACO. It coordinated care for approximately 1.3 million patients through roughly 11,000 contracted providers. Reported results consolidate subsidiaries and affiliated variable-interest entities (VIEs); some consolidated revenue and assets are not available for distribution to the parent.
Financial performance and position
| Metric | FY2022 | FY2021 | Change / context |
|---|---|---|---|
| Total revenue | $1,144.2 million | $773.9 million | Up 48% |
| Operating income | $104.3 million | $98.2 million | Up 6%; operating margin about 9.1%, versus 12.7% |
| Net income | $50.5 million | $49.3 million | Up 3% |
| Net income attributable to parent | $49.0 million | $73.9 million | Down 34%; reflects the change in noncontrolling-interest attribution |
| Diluted EPS | $1.08 | $1.63 | Down from prior year |
| Adjusted EBITDA | $140.0 million | $133.5 million | Non-GAAP measure; company changed its calculation during 2022 |
| Operating cash flow | $82.1 million | $70.3 million | Up from prior year |
| Cash and cash equivalents | $288.0 million | $233.1 million | Marketable securities were an additional $5.6 million |
| Total debt, before financing costs | $207.3 million | $188.0 million | Includes $180.0 million revolver borrowings |
| Working capital | $287.8 million | $283.4 million | Up $4.4 million |
Revenue growth was led by capitation, up 57% to $930.1 million, and fee-for-service revenue, up 86% to $49.5 million. Risk-pool settlements and incentives were $117.3 million, including $48.8 million of savings from the 2021 NGACO performance year recognized after settlement was finalized. Cost of services rose 58% to $944.7 million, faster than revenue, reflecting membership growth, a return toward pre-pandemic medical expense levels, and the Medicare value-based model. General and administrative expense increased 25% to $77.7 million.
Cash provided by operations was $82.1 million; investing activities used $7.1 million and financing activities used $20.1 million. The $400 million revolving facility had $180 million drawn at year-end, and its stated interest rate was 5.92%, versus 1.71% a year earlier. The company reported liquidity it believed sufficient to fund operations through at least February 2024. Debt is substantially secured, and the credit agreement includes leverage and interest-coverage covenants.
Material changes and unusual items
- Patients managed increased to approximately 1.3 million from 1.2 million; affiliated physician groups increased to 14 from 12.
- APAACO moved from the terminated NGACO program to the GPDC Model in 2022 and began participating in the ACO REACH Model on January 1, 2023. It selected Global risk and Total Care Capitation, exposing it to Medicare Part A and B spending for aligned beneficiaries, including out-of-network care.
- Acquisitions included Orma Health, Jade, Valley Oaks Medical Group, and All American Medical Group. Acquisition-related contingent consideration and integration, performance, and valuation assumptions are relevant to results.
- Unrealized investment losses increased to $21.3 million from $10.7 million, primarily due to declines in securities prices. Income from equity-method investments improved to $5.6 million from a $4.3 million loss.
- Noncontrolling interests shifted from a $24.6 million loss in 2021 to $1.5 million of income in 2022. The filing also reports $16.1 million of share-based compensation, up from $6.7 million.
Outlook, risks, and contingencies
For 2023, management guided to revenue of $1.3–$1.5 billion, net income of $49.5–$71.5 million, EBITDA of $89.5–$129.5 million, adjusted EBITDA of $120–$160 million, and diluted EPS of $0.95–$1.20. Guidance depends on assumptions about existing operations and market conditions; the filing cautions that actual results may differ materially. Net income and EBITDA guidance include APC Excluded Assets, while those assets’ gains and losses do not affect adjusted EBITDA or EPS.
- ACO risk: The preliminary 2023 ACO REACH expenditure benchmark was approximately $629.2 million. Under the selected risk track, the ACO could bear losses up to 100% of the first 25% of the benchmark—approximately $157.3 million—before risk corridors apply. Final performance is not known until reconciliation, generally in the following year.
- Medical claims: Medical liabilities were $84.3 million, including estimated incurred-but-not-reported claims. The auditor identified risk-pool settlements and IBNR valuation as critical audit matters because of estimation uncertainty and reliance on third-party data.
- Concentration and regulation: Four payors represented 59% of 2022 net revenue. The business is concentrated in California and subject to extensive healthcare rules, including corporate-practice-of-medicine and risk-bearing requirements. The company does not hold a Knox-Keene license and warns that regulatory interpretation could require changes to its arrangements.
- Structure and capital: Reliance on physician-owned VIEs and management agreements carries risks distinct from direct ownership. The filing also describes the $545 million AP-AMH loan and the related preferred-stock/dividend structure, as well as secured debt and covenant obligations.
- Other exposures: Risks include capitation losses if medical costs exceed payments, Medicare/Medicaid reimbursement or eligibility changes, staffing and acquisition execution, cybersecurity and privacy, and COVID-19-related disruption. Management reported no known pending or threatened regulatory investigation and stated affiliated IPAs were compliant with DMHC requirements at year-end; ordinary-course litigation and insurance-coverage risks remain.
The financial statements received an unqualified audit opinion, and the auditor also gave an unqualified opinion on internal control over financial reporting. Management reported effective disclosure controls and internal controls at December 31, 2022.
Most important facts for investors to verify
- Whether 2023 revenue, adjusted EBITDA, and diluted EPS guidance is achieved, and how the company’s revised non-GAAP adjusted EBITDA definition affects comparability.
- Final ACO REACH benchmark, quality-withhold recovery, aligned membership, claims experience, and any resulting shared savings or losses and cash-flow effects.
- Development and settlement of the $84.3 million medical-liability reserve and risk-pool receivables, including the $48.8 million NGACO settlement recognized in 2022.
- Payor concentration, growth in medical costs relative to capitation revenue, and the sustainability of margins as membership and Medicare-model participation expand.
- Debt and covenant headroom, refinancing and interest-rate exposure, and the availability of cash held in consolidated VIEs or classified as Excluded Assets.
- Acquisition performance and contingent payments, plus the effect of investment-price movements and noncontrolling-interest attribution on parent-level earnings.